Kamilov Kh M, Zaynutdinov N N
Center for the Development of Professional Qualifications of Medical Workers, Ministry of Health of the Republic of Uzbekistan, Tashkent, Uzbekistan.
OOO Nazar Medical, Tashkent, Uzbekistan.
Vestn Oftalmol. 2025;141(1):28-31. doi: 10.17116/oftalma202514101128.
Refractive anomalies are among the leading ocular conditions affecting the working-age population. One of them - high myopia - can cause severe and irreversible ocular changes, resulting in significant visual impairment or loss.
This study evaluated changes in vault height of phakic intraocular lenses (PIOL) and intraocular pressure (IOP) following the implantation of the ICL V5 (VICM5) lens in patients with high myopia.
The study included 60 patients. They were monitored for at least 24 months. Observation included measurement of clinical refraction, uncorrected visual acuity (UCVA), IOP, and the distance between the posterior surface of the optical part of the lens and the anterior surface of the crystalline lens (vault).
All surgeries were completed without complications. The safety and efficacy indices were 1.43 and 1.34, respectively. In 97 eyes (86%) with high myopia UCVA was equal to or better than preoperative values. The mean preoperative spherical equivalent was -10.59±3.4 D, which improved postoperatively to -0.5±0.75 D. Subsequently, the spherical equivalent remained within ±0.5 D in 89% of patients. The mean postoperative IOP was 15.86±3.30 mm Hg over the course of the 24-month follow-up. One month post-implantation, the vault height of the spherical lens ICL was 469.3±134.4 µm and 432.6±124.5 µm after 24 months (<0.001).
Implantation of the Visian ICL V5 lens is a safe and effective alternative refractive surgery method for the correction of high myopia.
屈光不正属于影响劳动年龄人口的主要眼部疾病。其中之一——高度近视——可导致严重且不可逆的眼部变化，造成显著视力损害或丧失。
本研究评估了高度近视患者植入ICL V5（VICM5）晶状体后有晶状体眼人工晶状体（PIOL）的拱高和眼压（IOP）的变化。
该研究纳入了60例患者。对他们进行了至少24个月的监测。观察内容包括临床验光、未矫正视力（UCVA）、眼压以及晶状体光学部分后表面与晶状体前表面之间的距离（拱高）测量。
所有手术均顺利完成，无并发症。安全性和有效性指标分别为1.43和1.34。在97只（86%）高度近视眼中，UCVA等于或优于术前值。术前平均等效球镜度为-10.59±3.4 D，术后改善至-0.5±0.75 D。随后，89%的患者等效球镜度保持在±0.5 D以内。在24个月的随访过程中，术后平均眼压为15.86±3.30 mmHg。植入后1个月，球形晶状体ICL的拱高为469.3±134.4 µm，24个月后为432.6±124.5 µm（<0.001）。
植入Visian ICL V5晶状体是矫正高度近视的一种安全有效的屈光手术替代方法。
